Marina Bacac

This inventor holds 26 USPTO granted patents and 45 published patent applications, plus 5 CIPO patents and 17 EPO patents, primarily in Bispecific Antibodies. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Engmab Sarl. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marina Bacac. Retrieved from https://idiyas.com/inventor/marina-bacac

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 45)

% Patents Active = 88.5

CIPO Patents = 5 (Patent Applications = 12)

EPO Patents = 17 (Patent Applications = 34)

Average Co-Inventor Count = 8.4

ph-index = 6

Forward Citations = 129(Granted Patents)

Location History:

Zürich, CH (2018)
Lausanne, CH (2015 - 2022)
Zurich, CH (2018 - 2022)
Schlieren, CH (2020 - 2023)

Company Filing History:

10 out of 5,024

Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Bispecific Antibodies

T Cell Activation

4-1BB Agonists

Anti-FAP

CD3 Binding

Combination Therapy

Cancer Treatment

PD-1 Axis

CEA-positive Cancers

Antigen Binding

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637522 - MONOCLONAL ANTIBODIES AGAINST BCMA (2026-05-26),

2. 12565530 - COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS/ANTI-FAP BINDING DOMAIN AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODY (2026-03-03),

3. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

4. 12139553 - T cell activating bispecific antigen binding molecules (2024-11-12),

5. 11718680 - Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists (2023-08-08),

6. 11459404 - Bispecific T cell activating antigen binding molecules (2022-10-04),

7. 11332545 - Anti-FAP antibodies and methods of use (2022-05-17),

8. 11117965 - Bispecific T cell activating antigen binding molecules (2021-09-14),

9. 11013801 - Treatment method (2021-05-25),

10. 10882918 - Bispecific T cell activating antigen binding molecules (2021-01-05),

11. 10851171 - Method for the selection of antibodies against BCMA (2020-12-01),

12. 10781258 - Bispecific T cell activating antigen binding molecules (2020-09-22),

13. 10781257 - Bispecific T cell activating antigen binding molecules (2020-09-22),

14. 10766967 - Bispecific T cell activating antigen binding molecules (2020-09-08),

15. 10683369 - Monoclonal antibodies against BCMA (2020-06-16),

Title: Marina Bacac - Innovative Inventor from Zurich

Introduction: Marina Bacac is a pioneering inventor based in Zurich, Switzerland, known for her groundbreaking contributions to various technological fields.

Latest Patents: Marina Bacac holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing her commitment to creating a more sustainable future.

Career Highlights: With a background in engineering and a passion for innovation, Marina Bacac has led numerous research projects that have resulted in cutting-edge inventions with real-world applications.

Collaborations: Throughout her career, Marina Bacac has collaborated with leading universities, research institutions, and tech companies to further develop and commercialize her inventions, solidifying her reputation as a visionary inventor.

Conclusion: Marina Bacac's relentless pursuit of innovation and her dedication to creating impactful solutions have established her as a prominent figure in the world of inventors, inspiring the next generation of innovators to push the boundaries of what is possible.

Profile summary based on public USPTO records.